Issue link: https://viewer.e-digitaledition.com/i/236367
COVER FEATURE Timothy C. Oskin, MD Stephen A. Olenchock, DO Darren M. Traub, DO 14 segment of aorta below the aneurysm is too short to permit grafting, due to the possibility of graft migration or leakage. For these patients, fenestrated stent grafts provide the possibility of treatment. With openings or "fenestrations" for renal or mesenteric arteries, fenestrated grafts allow more range in placing stents. "We can use a catheter through the fenestrations to bridge the kidney artery, aligning the stent graft perfectly," Dr. Oskin says. "Now we can include some patients who would not have a stent graft otherwise, eliminating the need to perform complex open surgery in which we would need to stop the blood flow to the kidneys for a period of time, thus placing the kidneys at risk." Again, the vascular physicians at St. Luke's are able to tailor the procedure to best fit the patient's needs in order to reduce risk, shorten recovery and optimize long-term results. New Approaches to Atrial Fibrillation While medication or traditional catheter ablation alleviates symptoms in most cases of paroxysmal atrial fibrillation (episodes that start and stop on their own), catheter ablation is less effective in those with sustained atrial fibrillation (episodes lasting longer than seven days). Among patients who experience persistent (greater than seven days) or longstanding persistent (greater than one year) atrial fibrillation, approximately 50 percent or more will not be adequately helped by a single procedure involving catheter ablation. For those patients, St. Luke's has a new solution: a technique that combines transvenous catheter ablation with thorascopic surgery to ensure accurate and complete ablation of the fibrillation's focal points and reduces the atria's ability to sustain atrial fibrillation. Upon learning of this innovative procedure, Dr. Olenchock and Darren Traub, DO, electrophysiologist at St. Luke's University Health Network, wanted to see it for themselves before bringing it to their patients. Together, they traveled to Maastricht, the Netherlands, to study alongside the surgeons who developed hybrid thorascopic surgical and transvenous catheter ablation. "This technique appears likely to offer a | Eastern Pennsylvania/NW New Jersey MD NEWS I MDNEWS.COM more successful approach for patients with persistent and longstanding persistent atrial fibrillation," Dr. Traub says. "The surgeon inserts small ports into the chest wall and performs radiofrequency ablation from outside the heart. Immediately following, the electrophysiologist accesses the heart transvenously and completes any gaps in the surgeon's ablation lines. The electrophysiologist also checks to see that the surgical lesions accomplished the desired electrical endpoint for ablation. The procedure represents the best of both worlds because the surgeon can truly visualize what he or she is doing; also, the surgeon is not limited by blood circulating around the ablation catheter. He or she can create more durable ablation lines, while the electrophysiologist has the tools and training to check interoperatively for electrical gaps. We are also able to exclude the left atrial appendage during the procedure, which we believe is responsible for up to 90 percent of atrial fibrillation-related strokes." The St. Luke's culture encourages exactly this type of innovation, especially when the goal is bringing advanced techniques to patients in the Lehigh Valley who would not otherwise have ready access to them. With the availability of the hybrid OR, physicians and patients will benefit from increasing numbers of crossdisciplinary treatments such as the hybrid atrial fibrillation procedure. ECMO for Acute Heart and Respiratory Failure Long utilized for babies in respiratory distress, extracorporeal membrane oxygenation may also be used for adults in danger of acute cardiac or respiratory failure, keeping them alive while their hearts or lungs recover. At St. Luke's, this lifesaving therapy helps patients who suffer heart failure following myocardial infarction or severe acute influenza, among other conditions. As ECMO patients typically have a very low survival rate without the intervention, this is an important new therapy offered by St. Luke's. "My partner, Jose Amortegui, MD, had become familiar with ECMO at the University of Maryland Medical Center," says Raymond Fitzpatrick, MD, cardiothoracic surgeon at St. Luke's University Health Network. "When he came here two and a

